2023年6月2日 · Everolimus is an inhibitor of a kinase called mammalian target of rapamycin (mTOR), which plays an important role in a pathway that regulates things such as how cells in …

Inhibition of mTOR, the molecular target of everolimus, extends the lifespan of model organisms including mice, [37] and mTOR inhibition has been suggested as an anti-aging therapy.

2023年5月4日 · Inhibition of the protein kinase mechanistic target of rapamycin (mTOR) with the Food and Drug Administration (FDA)-approved therapeutic rapamycin promotes health and …

2012年2月9日 · Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, …

Several clinical trials have shown that the mTOR inhibitor everolimus could improve patient outcomes in several subtypes of breast cancer, including hormone receptor–positive, human …

2024年5月22日 · Everolimus is an mTOR inhibitor that is also a macrolide immunosuppressant. It works by preventing the actions of mTOR, which plays a vital role in cell growth and …

Everolimus (RAD001) is an oral protein kinase inhibitor of the mTOR (mammalian target of rapamycin) serine/threonine kinase signal transduction pathway.

Everolimus is a mTOR inhibitor that binds with high affinity to the FK506 binding protein-12 (FKBP-12), thereby forming a drug complex that inhibits the activation of mTOR.

mTOR (mechanistic target of rapamycin) functions as the central regulator for cell proliferation, growth and survival. Up-regulation of proteins regulating mTOR, as well as its downstream …

Everolimus is a type of targeted drug called an mTOR blocker (inhibitor). It is a treatment for several cancers. Find out about how you have it and more.